AlphAIalphai — Financial news for AI agents
investing.comSEP 71 min read$NVS

Novartis shares fall after heart drug fails late-stage trial

Novartis AG shares dropped over 3% after its experimental drug pelacarsen failed to reduce heart attacks, strokes, and other serious heart problems in a late-stage trial. The Lp(a)HORIZON trial involved over 8,000 patients with high lipoprotein(a) levels. Despite lowering blood fat levels, the drug did not reduce cardiovascular events, raising questions about similar treatments from Amgen and Eli Lilly. Novartis's chief medical officer acknowledged the disappointing results but noted the data ad

Original reporting
investing.com
Published Sep 7, 2026, 7:56 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 7, 2026, 8:06 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefTechnology
Primary signal
$NVS
Bearish
high confidence
Mentioned
$NVS
Relevance
8/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$NVSBearishHigh
01

Why it matters

The failure raises doubts about the viability of Lp(a)‑targeted therapies and may affect peer companies developing similar drugs.

02

Market read

First report of a major cardiovascular trial failure; immediate price impact and broader biotech sector implications.

03

Timing

Monday pre‑market

Relevance 8/10Novelty 9/10Timing: Monday pre‑market

Background

Novartis announced that its experimental drug pelacarsen did not meet primary endpoints in the Lp(a)HORIZON trial involving >8,000 patients.

Company-level read

Ticker impact

$NVSBearishHigh confidence
Context

Novartis shares fell >3% after pelacarsen failed to reduce heart attacks, strokes, and cardiovascular events in the Lp(a)HORIZON trial.

Expected impact

Further downside pressure on NVS as investors reassess cardiovascular pipeline.

Evidence & confidence

First disclosure of a major trial failure for a flagship lipid‑lowering program; market already reacted with a 3% drop.

Market effects

Sector

Setback may dampen biotech and pharma sentiment, especially firms pursuing Lp(a)‑lowering strategies.

Regional

European markets could see pressure on listed pharma stocks.

Global

Potential ripple effect on global biotech valuations and pipeline expectations.

Key entities

  • company
    Novartis AG

    Swiss pharmaceutical giant, ticker NVS.

  • drug
    pelacarsen

    Experimental Lp(a)‑lowering therapy.

Read at source← All news

Related articles

SEP 7
$NVSMed

Novartis India to acquire Minipress, Pfizer’s high blood pressure drug, for ₹1,250 crore

Novartis India will acquire Pfizer's Minipress and Minipres trademarks in India, along with related intellectual property, for ₹1,250 crore. The deal includes Minipress XL, a high blood pressure drug with ₹228.6 crore revenue in July 2026. Pfizer will discontinue Minipress XL sales in India, receiving a $13.9 million lump-sum payment. Novartis India shares rose 2.9%, while Pfizer's shares fell 0.8%.

cnbctv18.com2 min
SEP 7
$NVSMedAI 8/10

Novartis India acquires Pfizer Minipress IP rights for ₹1,250 crore

Novartis India acquired the trademarks 'Minipress' and 'Minipres' along with related IP rights from Pfizer for ₹1,250.001 crore. The deal values the brand at approximately 5.5 times its trailing twelve-month revenue. Separately, Novartis' Phase III Lp(a)HORIZON trial for pelacarsen failed to meet its primary endpoint, showing no reduction in cardiovascular events despite lower Lp(a) levels.

scanx.trade3 min
SEP 5
$NVSMedAI 8/10

Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines

Novartis and Ionis' RNA drug, pelacarsen, failed to reduce heart attack, stroke, and death risks in a Phase 3 trial, despite lowering Lp(a) levels. Novartis stated the results were disappointing but may inform future cardiovascular approaches. Analysts noted the failure raises questions about similar therapies and potential impacts on ongoing trials. The drug was expected to generate significant revenue if successful.

biopharmadive.com2 min
SEP 5
$NVSHighAI 9/10

Novartis, Ionis’ experimental heart drug misses key goal in trial

Novartis and Ionis Pharmaceuticals reported that their experimental heart drug, pelacarsen, failed to reduce the risk of major heart attacks and strokes in a late-stage trial. The drug, targeting genetically inherited cholesterol Lp(a), lowered Lp(a) levels but did not meet its primary endpoint. Novartis shares fell 5%, and Ionis shares dropped 12% in aftermarket trading. The companies plan to present full trial data at an upcoming medical congress.

manilatimes.net2 min
SEP 5
$NVSHighAI 8/10

Novartis' Pelacarsen Fails To Meet Primary Endpoint In Phase III Lp(a)HORIZON Trial

Novartis' phase III Lp(a)HORIZON trial of pelacarsen failed to meet its primary endpoint, as the drug did not reduce cardiovascular events compared to placebo, despite lowering Lp(a) levels. The company acknowledged the results were not as hoped but may advance scientific understanding. NVS shares closed at $159.99, down 1.90%, and rose to $162.90 in afterhours trading.

rttnews.com2 min
Novartis shares fall after heart drug fails late-stage trial — alphai